282 related articles for article (PubMed ID: 9923781)
21. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil.
Mimouni D; Anhalt GJ; Cummins DL; Kouba DJ; Thorne JE; Nousari HC
Arch Dermatol; 2003 Jun; 139(6):739-42. PubMed ID: 12810504
[TBL] [Abstract][Full Text] [Related]
22. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
23. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus.
Bongiorno MR; Pistone G; Doukaki S; Aricò M
Int J Dermatol; 2010 Jun; 49(6):693-9. PubMed ID: 20618478
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial and the treatment of pemphigus vulgaris.
Margolis DJ
J Invest Dermatol; 2010 Aug; 130(8):1964-6. PubMed ID: 20631749
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
Dooley MA; Jayne D; Ginzler EM; Isenberg D; Olsen NJ; Wofsy D; Eitner F; Appel GB; Contreras G; Lisk L; Solomons N;
N Engl J Med; 2011 Nov; 365(20):1886-95. PubMed ID: 22087680
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
Chan TM; Li FK; Tang CS; Wong RW; Fang GX; Ji YL; Lau CS; Wong AK; Tong MK; Chan KW; Lai KN
N Engl J Med; 2000 Oct; 343(16):1156-62. PubMed ID: 11036121
[TBL] [Abstract][Full Text] [Related]
27. Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.
Werth VP; Joly P; Mimouni D; Maverakis E; Caux F; Lehane P; Gearhart L; Kapre A; Pordeli P; Chen DM;
N Engl J Med; 2021 Jun; 384(24):2295-2305. PubMed ID: 34097368
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.
Richardson PD; James PD; Ryder SD
J Hepatol; 2000 Sep; 33(3):371-5. PubMed ID: 11019991
[TBL] [Abstract][Full Text] [Related]
29. Localized Kaposi's sarcoma in a patient with pemphigus vulgaris.
Avalos-Peralta P; Herrera A; Ríos-Martín JJ; Pérez-Bernal AM; Moreno-Ramírez D; Camacho F
J Eur Acad Dermatol Venereol; 2006 Jan; 20(1):79-83. PubMed ID: 16405614
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
Vyas N; Patel NS; Cohen GF
J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
[TBL] [Abstract][Full Text] [Related]
31. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.
Firooz A; Ghandi N; Hallaji Z; Chams-Davatchi C; Valikhani M; Karbakhsh Davari M
Arch Dermatol; 2008 Sep; 144(9):1143-7. PubMed ID: 18794458
[TBL] [Abstract][Full Text] [Related]
32. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
[TBL] [Abstract][Full Text] [Related]
33. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.
Megahed M; Schmiedeberg S; Becker J; Ruzicka T
J Am Acad Dermatol; 2001 Aug; 45(2):256-9. PubMed ID: 11464188
[TBL] [Abstract][Full Text] [Related]
34. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus.
Williams JV; Marks JG; Billingsley EM
Br J Dermatol; 2000 Mar; 142(3):506-8. PubMed ID: 10735959
[TBL] [Abstract][Full Text] [Related]
35. A case with Listeria meningitis during administration of mycophenolate mofetil for pemphigus vulgaris.
Akyol M; Ozçelik S; Engin A; Ozel l ahin G
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1447-8. PubMed ID: 17958877
[No Abstract] [Full Text] [Related]
36. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.
Orth T; Peters M; Schlaak JF; Krummenauer F; Wanitschke R; Mayet WJ; Galle PR; Neurath MF
Am J Gastroenterol; 2000 May; 95(5):1201-7. PubMed ID: 10811328
[TBL] [Abstract][Full Text] [Related]
37. Outcome of pemphigus vulgaris.
Kavusi S; Daneshpazhooh M; Farahani F; Abedini R; Lajevardi V; Chams-Davatchi C
J Eur Acad Dermatol Venereol; 2008 May; 22(5):580-4. PubMed ID: 18194237
[TBL] [Abstract][Full Text] [Related]
38. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study.
De Simone C; Caldarola G; Perino F; Venier A; Guerriero G
Dermatol Ther; 2012; 25(2):219-22. PubMed ID: 22741942
[TBL] [Abstract][Full Text] [Related]
39. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy.
Fallatah HI; Akbar HO
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):517-22. PubMed ID: 21780898
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study.
Ioannides D; Apalla Z; Lazaridou E; Rigopoulos D
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):855-60. PubMed ID: 21752101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
